Results 131 to 140 of about 2,968 (201)

Effective Use of Olanzapine for Chemotherapy-Induced Nausea and Vomiting in a Patient Receiving Dose-Adjusted Rituximab, Etoposide, Prednisone, Vincristine (Oncovin®), Cyclophosphamide, and Doxorubicin (R-EPOCH): A Case Report. [PDF]

Cureus
Shimada H, Ohgami M, Kurokawa Y, Tachihara S, Sugaya A.   +4 more
europepmc   +1 more source

Palonosetron versus tropisetron with dexamethasone for prevention of postoperative nausea and vomiting in pediatric adenotonsillectomy: a single center, randomized controlled trial. [PDF]

Front Med (Lausanne)
Chen H, Sun L, Zheng J, Gu H.
europepmc   +1 more source

Pharmacokinetics, safety, and efficacy of mixed formulation of fosrolapitant and palonosetron (HR20013) in combination with dexamethasone in patients with solid tumors scheduled for highly emetogenic cisplatin-based chemotherapy: a phase I trial. [PDF]

BMC Med
Zhao Y, Ma Y, Yin T, Qin Z, Liu L, Kong G, Zhang R, Huang Y, Zhang L, Zhao H.   +9 more
europepmc   +1 more source

5-HT regulates resistance to aumolertinib by attenuating ferroptosis in lung adenocarcinoma. [PDF]

EMBO Mol Med
Feng Y, He Y, Zuo R, Gong W, Gao Y, Wang Y, Wang Y, Chen W, Chen L, Luo Y, Yuan D, Chen P, Guo H.   +12 more
europepmc   +1 more source

Patient factors and costs associated with prophylactic neurokinin-1 receptor antagonist use among women with invasive breast cancer. [PDF]

J Manag Care Spec Pharm
Kamat S, Brown BR, Cohen SA, Vyas A.
europepmc   +1 more source

STOP-CINV Study: Safety and Efficacy of IV Akynzeo® (Fosnetupitant 235 mg and Palonosetron 0.25 mg) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Indian Patients. [PDF]

Cureus
Shukla P, Valame S, Nanda S, Shakya NK, Verma AK, Hanji A, Pednekar A, Bhagat S, Patil S, Petare AU, Bhushan S, Barkate H.   +11 more
europepmc   +1 more source

A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy. [PDF]

Support Care Cancer
Harikul W, Nimmannit A, Laocharoenkeat A, Phisalprapa P, Kositamongkol C, Thongkijpreecha P, Ithimakin S.   +6 more
europepmc   +1 more source

Comparative Efficacy of Fosnetupitant and Fosaprepitant for Delayed Vomiting in Patients Receiving Irinotecan-Oxaliplatin Combination Chemotherapy: A Retrospective Propensity Score-Matched Study. [PDF]

Cancer Manag Res
Maeda K, Kawada K, Hayashi T, Koyama S, Ishida T, Yoshioka T, Fukuda H, Horikawa I, Aizawa F, Niimura T, Yagi K, Goda M, Izawa-Ishizawa Y, Ishizawa K.   +13 more
europepmc   +1 more source

Efficacy of steroid-omitting antiemetic therapy in patients with advanced pancreatic cancer receiving nano-liposomal irinotecan plus fluorouracil and leucovorin. [PDF]

Support Care Cancer
Tokito Y, Ishigaki K, Nara K, Endo G, Nishio H, Fukuda K, Suzuki T, Sato Y, Takahara N, Boku N, Fujishiro M.   +10 more
europepmc   +1 more source

Validation of Steroid-Sparing Therapy in Patients Receiving Oxaliplatin-based Chemotherapy: A before-and-after Prospective Observational Study. [PDF]

Asian Pac J Cancer Prev
Yamamoto Y, Watanabe N, Goshima A, Hayashi H, Fukuoka T, Ando M, Kawahara M.   +6 more
europepmc   +1 more source